Membrane-associated glucocorticoid receptor (mGR) (mGR)

The membrane-associated glucocorticoid receptor (mGR) is a plasma membrane-localized variant of the classical cytosolic glucocorticoid receptor (NR3C1) that facilitates rapid, non-genomic physiological responses (Strehl et al., 2011; UniProt P04150). While the classical receptor functions primarily as a ligand-activated transcription factor in the nucleus, mGR initiates immediate biochemical changes through secondary messenger systems like the MAPK, PI3K/Akt, and Src kinase pathways (Buttgereit et al., 2015). This receptor is predominantly expressed on the surface of activated immune cells, particularly monocytes and B-cells, and its expression levels correlate with disease activity in chronic inflammatory conditions such as rheumatoid arthritis and systemic lupus erythematosus (Spies et al., 2006). Conventional glucocorticoid drugs, including dexamethasone and prednisolone, interact with mGR to produce rapid immunosuppressive effects that occur within minutes, preceding the slower genomic changes (Löwenberg et al., 2007). Research into mGR is focused on developing selective or membrane-impermeable glucocorticoids to harness these rapid anti-inflammatory actions while potentially reducing the systemic side effects associated with the genomic pathway, such as metabolic dysfunction and bone loss (Stahn & Buttgereit, 2008). Consequently, mGR serves as both a potential therapeutic target and a biomarker for monitoring glucocorticoid sensitivity in inflammatory diseases.

Other names

mGRMembrane glucocorticoid receptorPlasma membrane-bound glucocorticoid receptorSurface glucocorticoid receptorMembrane-bound glucocorticoid receptor

Agonist binding to the membrane-associated glucocorticoid receptor triggers rapid, non-genomic signaling pathways, including the activation of kinases such as MAPK, PI3K, and Src, leading to immediate anti-inflammatory and immunosuppressive effects.